Clinical Data Show Long Acting Human Growth Hormone ARX201 Is Safe And Well Tolerated (Medical News Today, 14 November 2008)

18 Nov 2008

Results of a phase I/II clinical trial by Ambrx Inc. showing that ARX201, the company's long-acting human growth hormone (hGH) analogue, normalised insulin-like growth factor I (IGF-I) levels, were presented at the International Congress of Endocrinology Conference in Rio de Janeiro.